- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02832882
RFA for Small HCC With No-touch Technique Using Octopus Electrode
March 17, 2021 updated by: Jeong Min Lee, Seoul National University Hospital
Radiofrequency Ablation for Small Hepatocellular Carcinoma Using Octopus Electrode and No-touch Technique: Preliminary Study
In this study, the investigators are going to prospectively compare the clinical outcomes (technical success rate, 12 month local tumor progression rate, complication rate, tumor seeding rate) of Radiofrequency ablation (RFA) with octopus electrode and no-touch technique for Hepatocellular carcinoma (HCC) to those of RFA with conventional tumor puncture method with the same device.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
118
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Child-Pugh class A
- patient with 1cm-2.5cm sized HCC
- 1 or 2 HCCs
- being referred for curative purpose of RFA
- sign informed consent
Exclusion Criteria:
- maximum tumor diameter greater than 2.5cm
- Child-Pugh class B or C
- more than 3 HCC lesions
- invisible tumor even after US/CT or US/MR fusion
- presence of vascular tumor thrombosis or extrahepatic metastasis
- severe coagulopathy (PLT < 50K, PT < 50% of normal range)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: No-touch RFA arm
No-touch RFA arm indicates RFA procedure using Octopus electrode and no touch technique.
|
No-touch RFA indicates RFA without tumor puncture.
In this study, no-touch RFA is performed using Octopus electrodes.
|
|
Active Comparator: Conventional tumor puncture RFA arm
Conventional tumor puncture RFA arm indicates RFA procedure using Octopus electrode and conventional tumor puncture technique.
|
Conventional tumor puncture RFA indicates routine procedure of RFA in our institution.
In this study, RFA procedure is performed using Octopus electrodes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
12 month local tumor progression (LTP) rate
Time Frame: 12 month after RFA
|
12 month after RFA
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
tumor seeding rate
Time Frame: 12 months after RFA
|
incidence of tract seeding after RFA.
|
12 months after RFA
|
|
Complication rate related with RFA
Time Frame: 1 month
|
RFA-related complication rate such as death, abscess, bleeding..etc.
|
1 month
|
|
Technical success rate
Time Frame: 1 months
|
presence or absence of residual lesion on follow-up imaging
|
1 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ablation time
Time Frame: 3 days after RFA
|
ablation time for tumor ablation
|
3 days after RFA
|
|
Intrahepatic distant mets
Time Frame: 12 months after RFA
|
incidence of intrahepatic distant metastasis after RFA
|
12 months after RFA
|
|
Extrahepatic distant mets
Time Frame: 12 months after RFA
|
incidence of extrahepatic distant metastasis after RFA
|
12 months after RFA
|
|
Technical efficacy 1
Time Frame: 2 days after RFA
|
Assessment of ablative margin using score 1-4 (1: residual tumor; 4: equal to or larger than 5mm) in side-by-side comparison of pre-RFA CT/MR and post-RFA CT using visual assessment
|
2 days after RFA
|
|
Technical efficacy 2
Time Frame: 2 days after RFA
|
Assessment of ablative margin using score 1-4 (1: residual tumor; 4: equal to or larger than 5mm) in side-by-side comparison of pre-RFA CT/MR and post-RFA CT using registration software
|
2 days after RFA
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 21, 2016
Primary Completion (Actual)
September 11, 2018
Study Completion (Actual)
January 17, 2020
Study Registration Dates
First Submitted
June 3, 2016
First Submitted That Met QC Criteria
July 11, 2016
First Posted (Estimate)
July 14, 2016
Study Record Updates
Last Update Posted (Actual)
March 22, 2021
Last Update Submitted That Met QC Criteria
March 17, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SNUH-2016-2244
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.